FindTrial
Sign In

CA-4948

DRUG5 trials

Sponsors

Curis Inc., University of Leipzig, Washington University School of Medicine

Conditions

Acute Myelogenous Leukemia (AML) or higher-risk Myelodysplastic Syndrome (MDS).AnemiaChronic Lymphocytic Leukemia and Other B-cell MalignanciesEsophageal CancerEsophagus CancerGastric CancerGastroesophageal Junction CancerMyelodysplastic Syndromes

Phase 1

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
RecruitingNCT05187182
Washington University School of MedicineEsophageal Cancer, Esophagus Cancer, Gastric Cancer +2
Start: 2023-06-02End: 2029-04-30Target: 42Updated: 2026-04-27
An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma
RecruitingCTIS2024-513312-95-00
Curis Inc.Part A2. Relapsed or Refractory Hematologic Malignancy. (Enrolment is closed), Part B+C. Primary central nervous system lymphoma (PCNSL)
Start: 2023-05-30Target: 69Updated: 2025-09-25
A Phase 1/2A, Open Label Dose Escalation and Cohort Expansion Study of Orally Administered CA-4948 (IRAK4i) as a Monotherapy in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
CompletedCTIS2024-513313-13-00
Curis Inc.Acute Myelogenous Leukemia (AML) or higher-risk Myelodysplastic Syndrome (MDS).
Start: 2020-12-09End: 2025-02-26Target: 70Updated: 2024-09-30

Phase 2

Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948
TerminatedNCT05178342
University of LeipzigAnemia, Myelodysplastic Syndromes
Start: 2022-01-01End: 2024-07-31Updated: 2024-08-13
A Phase 2 Study of Emavusertib in Combination with an Approved Bruton Tyrosine Kinase Inhibitor in Patients with Chronic Lymphocytic Leukemia and Other B-cell Malignancies
Not yet recruitingCTIS2025-523600-68-00
Curis Inc.Chronic Lymphocytic Leukemia and Other B-cell Malignancies
Target: 40Updated: 2026-03-16

Related Papers

Canakinumab or emavusertib for anemia in lower-risk MDS: results of the CANFIRE and LUCAS phase 2, open-label, multicenter trials
Communications Medicine2026-09-16
Phase I trial of emavusertib (CA-4948) in combination with FOLFOX/PD-1 inhibitor +/- trastuzumab for untreated, unresectable gastric and esophageal cancer.
Journal of Clinical Oncology2026-01-10
Phase I trial of CA-4948, an IRAK4 inhibitor, in combination with FOLFOX/PD-1 inhibitor +/- trastuzumab for untreated unresectable gastric and esophageal cancer.
Journal of Clinical Oncology2022-06-013 citations